<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phenylephrine (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phenylephrine (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phenylephrine (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12288" href="/d/html/12288.html" rel="external">see "Phenylephrine (topical): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16037" href="/d/html/16037.html" rel="external">see "Phenylephrine (topical): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9504772"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Avedana Hemorrhoid Pain Relief [OTC];</li>
<li>Avedana Hemorrhoidal [OTC];</li>
<li>Avedana Hemorroidal Cooling [OTC];</li>
<li>GRX Hemorrhoidal [OTC] [DSC];</li>
<li>Hemorrhoidal Cooling [OTC];</li>
<li>Hemorrhoidal [OTC];</li>
<li>Major-Prep Hemorrhoidal [OTC] [DSC];</li>
<li>Preparation H [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9508681"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha-Adrenergic Agonist;</li>
<li>
                        Antihemorrhoidal Agent</li></ul></div>
<div class="block doa drugH1Div" id="F9504930"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="93c6026c-8da1-4676-a6b0-f8bf5611d875">Hemorrhoids, anorectal pain/itch</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemorrhoids, anorectal pain/itch:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Combine with dietary modifications, bowel hygiene, and warm sitz baths for best results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29420423','lexi-content-ref-35119707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29420423','lexi-content-ref-35119707'])">Ref</a></span>). General dosing guidelines provided; refer to specific product labeling for dosing instructions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ointment:</i>
<b>Topical, rectal:</b> Apply to rectal area or by applicator into rectum, as needed, up to 4 times/day (eg, morning, night, after bowel movements).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Suppository:</i>
<b>Rectal:</b> Insert 1 suppository, as needed, up to 4 times/day (eg, morning, night, after bowel movements).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F57284609"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F57284610"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F9504931"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9504929"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16037" href="/d/html/16037.html" rel="external">see "Phenylephrine (topical): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f78d1b78-a9f7-4052-a727-9b1fc3054b15">Hemorrhoids, anorectal protection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemorrhoids, anorectal protection:</b> Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ointment:</i> Topical or rectal: Apply to rectal area or by applicator into rectum up to 4 times daily (eg, morning, night, and after bowel movements)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Suppository:</i> Rectal: Insert 1 suppository into rectum up to 4 times daily (eg, morning, night, and after bowel movements)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F9504820"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">Rare systemic effects may occur.</p></div>
<div class="block war drugH1Div" id="F9504818"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): For external use only. When used for self-medication (OTC), notify health care provider prior to use if you have diabetes, heart disease, high BP, thyroid disease, difficultly in urination due to enlargement of the prostate gland, or are currently taking medications for high BP or depression. Discontinue use and notify health care provider if condition worsens or does not improve within 7 days or if bleeding occurs; or if introduction of applicator into rectum causes additional pain.</p></div>
<div class="block foc drugH1Div" id="F9505022"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avedana Hemorroidal Cooling: 0.25% (25.5 g) [contains edetate (edta) disodium, methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemorrhoidal Cooling: 0.25% (51 g) [contains methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Preparation H: 0.25% (26 g, 51 g) [contains edetate (edta) disodium, methylparaben, polysorbate 80, propylene glycol, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, Rectal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avedana Hemorrhoid Pain Relief: 0.25% (57 g) [contains benzoic acid, corn oil, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GRX Hemorrhoidal: 0.25% (43 g [DSC]) [contains benzoic acid, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemorrhoidal: 0.25% (56 g, 57 g) [contains benzoic acid, cetyl alcohol, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemorrhoidal: 0.25% (56 g, 57 g) [contains benzoic acid, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Major-Prep Hemorrhoidal: 0.25% (57 g [DSC]) [contains benzoic acid, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Preparation H: 0.25% (28 g, 57 g) [contains benzoic acid, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suppository, Rectal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avedana Hemorrhoidal: 0.25% (12 ea, 24 ea) [contains corn starch, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemorrhoidal: 0.25% (12 ea) [contains corn starch, methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hemorrhoidal: 0.25% (12 ea, 24 ea) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Preparation H: 0.25% (12 ea, 24 ea, 48 ea) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Preparation H: 0.25% (12 ea, 24 ea, 48 ea) [contains corn starch, methylparaben, propylparaben]</p></div>
<div class="block geq drugH1Div" id="F13307666"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322414"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Avedana Hemorroidal Cooling External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-50% (per gram): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Preparation H External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-50% (per gram): $0.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Avedana Hemorrhoid Pain Relief Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-14-74.9% (per gram): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Preparation H Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-14-74.9% (per gram): $0.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Avedana Hemorrhoidal Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-88.44% (per each): $0.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suppository</b> (Preparation H Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per each): $0.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-88.44% (per each): $0.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57284611"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Ointment: Topical or rectal: For external and/or intrarectal use only. Prior to application, cleanse affected area by patting or blotting with appropriate cleansing wipe; gently dry by patting with a tissue or soft cloth prior to use. When using applicator for intrarectal use, remove protective cover from applicator and attach to tube. Lubricate applicator well, then gently insert into rectum. Thoroughly cleanse applicator after each use and replace protective cover.</p>
<p style="text-indent:-2em;margin-left:2em;">Suppository: For rectal use only. Prior to use, cleanse affected area by patting or blotting with appropriate cleansing wipe; gently dry by patting with a tissue or soft cloth prior to insertion. Remove foil wrapper.</p></div>
<div class="block admp drugH1Div" id="F52614399"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Ointment: Topical or rectal: For external and/or intrarectal use only. Prior to application, cleanse affected area by patting or blotting with appropriate cleansing wipe. Apply ointment to clean and dry rectal area at night, in the morning, and/or after each bowel movement (up to 4 times daily). When using applicator for intrarectal use, remove protective cover from applicator and attach to tube. Lubricate applicator well, then gently insert into rectum. Thoroughly cleanse applicator after each use and replace protective cover.</p>
<p style="text-indent:-2em;margin-left:2em;">Suppository: For rectal use only. Cleanse affected area by patting or blotting with appropriate cleansing wipe; gently dry by patting with a tissue or soft cloth prior to insertion. Remove foil wrapper. Insert into rectum at night, in the morning, and/or after each bowel movement (up to 4 times daily).</p></div>
<div class="block use drugH1Div" id="F9504812"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hemorrhoids, anorectal pain/itch:</b> Temporary relief of burning, local itching, and discomfort associated with hemorrhoids.</p></div>
<div class="block cyt drugH1Div" id="F13299871"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9504848"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Systemic): May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F11391519"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">When administered intravenously, phenylephrine crosses the placenta. Refer to the Phenylephrine (Systemic) monograph for details. There is limited information available supporting the use of topical agents for the treatment of hemorrhoids. Products containing phenylephrine should be used with caution in pregnant women, especially patients with hypertension or diabetes.</p></div>
<div class="block brc drugH1Div" id="F11391521"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if phenylephrine is excreted into breast milk.</p></div>
<div class="block pha drugH1Div" id="F9504887"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces local vasoconstriction.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58206970"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Neo synephrine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Isonefrine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Anu-med | Grx hemorrhoidal | Neo synephrine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Relief</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">I-glo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35119707">
<a name="35119707"></a>Brown S, Girling C, Thapa Magar H, et al. Guidelines, guidelines and more guidelines for haemorrhoid treatment: a review to sort the wheat from the chaff. <i>Colorectal Dis</i>. 2022;24(6):764-772. doi:10.1111/codi.16078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-topical-drug-information/abstract-text/35119707/pubmed" id="35119707" target="_blank">35119707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29420423">
<a name="29420423"></a>Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of hemorrhoids. <i>Dis Colon Rectum</i>. 2018;61(3):284-292. doi:10.1097/DCR.0000000000001030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-topical-drug-information/abstract-text/29420423/pubmed" id="29420423" target="_blank">29420423</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Preparation H ointment (phenylephrine topical) [prescribing information]. Madison, NJ: Pfizer; June 2019.</div>
</li>
<li>
<div class="reference">
                  Preparation H suppository (phenylephrine topical) [prescribing information]. Madison, NJ: Pfizer; received September 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9901 Version 323.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
